Methenamine amygdalate 250 mg

  • Product

    Methenamine amygdalate 250 mg, enteric-coated tablets

  • Authorisation

    Unlicensed medicine

  • Active ingredient

    Methenamine amygdalate 250 mg

  • Indication

    Uncomplicated urinary tract infections

  • Storage condition

    Below 25 °C

Methenamine amygdalate tablets are used for the treatment of uncomplicated urinary tract infections if conventional treatment with antibiotics is not effective or contraindicated and the patient does not tolerate or cannot swallow the licensed alternative XCYST® 500 mg (previously REFLUX® 500 mg) NL-RVG 04480.

Legal status

Methenamine amygdalate is an unlicensed medicine in the Netherlands. The Dutch Health Care Inspectorate (IGZ) has given permission for the supply.

Methenamine amygdalate is supplied “from-pharmacy-to-pharmacy” on named patient basis. An order signed by the pharmacist and a physician’s statement from the prescribing physician are required with every order.

Availability for (Hospital) Pharmacies

In the Netherlands, Methenamine amygdalate is supplied by ACE Apotheek. More information for (hospital) pharmacies in the Netherlands can be found on the website of ACE Apotheek.

(Hospital) Pharmacies outside the Netherlands that would like to know more about the availability of this product are welcome to contact us via our contact form.